Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.070 EUR
11.25 M EUR
169.63 M EUR
11.12 M
About BASILEA N
Sector
CEO
David Veitch
Headquarters
Allschwil
Website
Founded
2000
ISIN
CH0011432447
FIGI
BBG000N5LZC8
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000, and is headquartered in Allschwil, Switzerland.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on MUN exchange BASILEA PHARM.NA SF 1 stocks are traded under the ticker PK5.
We've gathered analysts' opinions on BASILEA PHARM.NA SF 1 future price: according to them, PK5 price has a max estimate of 106.29 EUR and a min estimate of 55.27 EUR. Watch PK5 chart and read a more detailed BASILEA PHARM.NA SF 1 stock forecast: see what analysts think of BASILEA PHARM.NA SF 1 and suggest that you do with its stocks.
Yes, you can track BASILEA PHARM.NA SF 1 financials in yearly and quarterly reports right on TradingView.
BASILEA PHARM.NA SF 1 is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
PK5 earnings for the last half-year are 1.67 EUR per share, whereas the estimation was 1.21 EUR, resulting in a 37.61% surprise. The estimated earnings for the next half-year are 3.45 EUR per share. See more details about BASILEA PHARM.NA SF 1 earnings.
BASILEA PHARM.NA SF 1 revenue for the last half-year amounts to 79.23 M EUR, despite the estimated figure of 110.18 M EUR. In the next half-year revenue is expected to reach 137.10 M EUR.
PK5 net income for the last half-year is 21.53 M EUR, while the previous report showed −23.02 M EUR of net income which accounts for 193.56% change. Track more BASILEA PHARM.NA SF 1 financial stats to get the full picture.
No, PK5 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 11, 2025, the company has 147.00 employees. See our rating of the largest employees — is BASILEA PHARM.NA SF 1 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BASILEA PHARM.NA SF 1 EBITDA is −5.18 M EUR, and current EBITDA margin is 14.39%. See more stats in BASILEA PHARM.NA SF 1 financial statements.
Like other stocks, PK5 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BASILEA PHARM.NA SF 1 stock right from TradingView charts — choose your broker and connect to your account.